(Q40482876)

English

Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

estrogen-receptor positive breast cancer

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Bruce E Hillner

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

language of work or name

0 references

publication date

1 September 2004

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

101

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1311-1322

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

21 January 2018

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

Aromatase inhibitors in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology Technology Assessment Working Group Update: Use of Aromatase Inhibitors in the Adjuvant Setting

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

The Markov process in medical prognosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

Decision-analytic model and cost-effectiveness evaluation of postmastectomy radiation therapy in high-risk premenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost-effectiveness of adding an electron-beam boost to tangential radiation therapy in patients with negative margins after conservative surgery for early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

Health system costs of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

Economic implications of hip fracture: health service use, institutional care and cost in Canada.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

International variations in hip fracture probabilities: implications for risk assessment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

Postmenopausal estrogens in prevention of osteoporosis. Benefit virtually without risk if cardiovascular effects are considered

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

Hip fractures in Finland between 1970 and 1997 and predictions for the future

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of health care delivered to adults in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

American Cancer Society guidelines for the early detection of cancer, 2003.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

Refined measurement of outcome for adjuvant breast carcinoma therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. International Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20492

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.20492

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40482876&oldid=1962181447"